ArriVent BioPharma (AVBP) Q4 2025 earnings summary

Executive summary

• Advanced firmonertinib with two pivotal Phase 3 programs targeting uncommon EGFR mutations in NSCLC, addressing high unmet need.

• ADC pipeline progressed, with ARR-217 in Phase 1 for gastrointestinal cancers and additional ADC candidates moving toward clinical development.

• Cash and investments of $312.8 million as of December 31, 2025, expected to fund operations into 3Q 2027.

Financial highlights

• Cash and investments totaled $312.8 million at year-end 2025.

• Net cash used in operations was $160.6 million in 2025, up from $70.2 million in 2024.

• Research and development expenses rose to $153.4 million in 2025, including a one-time upfront payment to Lepu Biopharma.

• General and administrative expenses increased to $24.2 million in 2025.

• Net loss widened to $166.3 million in 2025 from $80.5 million in 2024.

Outlook and guidance

• Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026.

• Enrollment underway for global pivotal Phase 3 PACC mutant NSCLC study for firmonertinib.

• IND filing for first-in-class ADC program ARR-002 planned for first half 2026.

• Phase 1 dose escalation for ARR-217 expected to complete and move to dose optimization in second half of 2026.